NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intellia Therapeutics Inc (NTLA) is not a strong buy for a beginner, long-term investor at this moment. While there are positive developments such as the FDA lifting clinical holds and analysts upgrading price targets, the company's financial performance shows significant losses, insider selling is high, and technical indicators suggest limited short-term upside potential. Given the investor's preference for long-term gains and the lack of strong proprietary trading signals, holding off on this stock for now is advisable.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200 and MACD above 0, suggesting positive momentum. However, RSI at 65.324 is neutral, and key resistance levels (R1: 16.477, R2: 17.349) are close to the current price of 15.87, indicating limited immediate upside potential.
FDA lifting clinical holds on key Phase 3 studies, allowing enrollment to resume.
Multiple analyst upgrades and increased price targets, with some firms projecting significant upside.
Revenue growth of 78.79% YoY in Q4 2025.
Insider selling has increased by 2235.78% over the last month, signaling potential lack of confidence from management.
Net income dropped by -25.69% YoY, and EPS fell by -34.65% YoY, reflecting poor profitability.
High implied volatility (115.
and historical volatility (61.
indicate uncertainty and potential risk.
In Q4 2025, revenue increased by 78.79% YoY to $23.02M, showing strong top-line growth. However, net income dropped to -$95.79M (-25.69% YoY), and EPS fell to -0.83 (-34.65% YoY), highlighting ongoing profitability challenges.
Analysts are generally positive, with multiple upgrades and increased price targets. Notable upgrades include JonesResearch to Buy with a $29 target and H.C. Wainwright raising the target to $30. However, some analysts remain cautious due to safety concerns and competition in the therapeutic space.
